EBS Nyse 2021 - 02 - 26

Emergent Biosolutions, Inc.

EBS | $2.04 9.68% 0.49% 930K

(0.0% 1d) (-25.9% 1m) (-81.9% 1y) (0.0% 2d) (0.0% 3d) (-6.1% 7d) (23.5% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 106,877,159
http://www.emergentbiosolutions.com
Sec Filling | Patents | 1834 employees

(US) Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

vaccine antibody military monkeypox smallpox tembexa injection

add to watch list Paper trade email alert is off

Press-releases

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -30.6% | O: -4.85% H: 2.18% C: -9.8%
AQST | $4.11 -8.67% -9.49% 2.3M

Health Technology

| 1.81% | O: -3.85% H: 2.35% C: -2.82%
biotech therapeutics

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -28.19% | O: 3.47% H: 0.0% C: 0.0%
narcan opioid save ongoing spray

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -22.82% | O: 0.83% H: 8.44% C: 4.53%

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Published: 2024-03-06 (Crawled : 22:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -42.94% | O: -16.26% H: 6.59% C: 1.47%
financial results

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
Published: 2024-02-29 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -41.87% | O: 3.75% H: 1.99% C: -2.71%
conference year financial

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Published: 2024-02-21 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| 22.37% | O: 11.84% H: 91.18% C: 59.41%
ceo

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Published: 2024-01-11 (Crawled : 13:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -14.29% | O: 3.69% H: 0.0% C: -6.67%
biothrax defense vaccine contract million

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Published: 2024-01-09 (Crawled : 12:30) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -13.89% | O: -0.93% H: 0.0% C: -2.8%
conference

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -10.14% | O: 2.42% H: 1.42% C: -5.19%
vaccine contract

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
Published: 2023-11-24 (Crawled : 12:30) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K

Health Technology

| -11.0% | O: -4.31% H: 9.0% C: 4.5%

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001367644-24-000049	4	2024-04-09	2024-04-07	Sell	F	585	164383
0001367644-24-000048	4	2024-04-09	2024-04-07	Sell	F	665	34274